Last reviewed · How we verify
GW642444 6.25
GW642444 is a glucagon receptor antagonist.
GW642444 is a glucagon receptor antagonist. Used for Type 2 diabetes.
At a glance
| Generic name | GW642444 6.25 |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
GW642444 works by binding to the glucagon receptor, thereby inhibiting glucagon's action and reducing glucose levels in the blood. This mechanism is thought to be beneficial for the treatment of type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Abdominal pain
Key clinical trials
- A Study to Investigate the Effect of Inhaling Single Doses of Different Formulations of GW642444M in Asthmatic Patients (PHASE1)
- A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GW642444 6.25 CI brief — competitive landscape report
- GW642444 6.25 updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI